BriaCell Expands Phase 3 Breast Cancer Trial with NYU Langone’s Perlmutter Cancer Center
Event summary
- BriaCell adds NYU Langone Health’s Perlmutter Cancer Center as a clinical site for its Phase 3 breast cancer study (Bria-ABC).
- The study evaluates Bria-IMT™ plus an immune checkpoint inhibitor vs. physician’s choice in advanced metastatic breast cancer.
- Interim analysis is planned after 144 patient events, with overall survival as the primary endpoint.
- Bria-IMT combination regimen has received FDA Fast Track designation.
- Patient enrollment has increased following a feature in Nature Medicine’s 2026 clinical trials list.
The big picture
BriaCell’s expansion into NYU Langone’s Perlmutter Cancer Center underscores growing institutional confidence in its Phase 3 trial, following heightened interest post-Nature Medicine feature. The FDA Fast Track designation further highlights the unmet need in advanced metastatic breast cancer, positioning Bria-IMT as a potential differentiator in the immunotherapy landscape. The trial’s progress will be critical in determining its competitive positioning against existing and emerging treatments.
What we're watching
- Trial Momentum
- Whether the addition of Perlmutter Cancer Center accelerates patient enrollment and data collection.
- Regulatory Pathway
- How the FDA Fast Track designation may influence future approval timelines.
- Clinical Efficacy
- The pace at which interim data will validate Bria-IMT’s combination regimen in advanced breast cancer.
Related topics